Pre-clinical & clinical exploratory poster presentations to highlight oncology results with Debio 0123, xevinapant, and Multilink[TM] technology for antibody drug conjugates
Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective WEE1 inhibitor), clinical exploratory results for xevinapant (IAP inhibitor), and 2 Multilink[TM] technology posters (antibody drug conjugate linker) at the 2022 Annual American Association for Cancer Research (AACR) meeting in New Orleans, Louisiana. The AACR conference serves as the focal point of the cancer research community to gather together and share advances in oncology science. Debiopharm and their partners’ poster presentations represent scientific progress in the research of these compounds leveraging novel modes of action and new delivery methods in development to treat cancer types with high unmet needs.
“Scientific cancer research is evolving quickly, bringing us the insights needed to better develop safer and more effective anti-tumor therapies. Our ultimate vision is to translate these findings into meaningful outcomes for patients in future clinical settings,” explained Carolina Haefliger, Head of Translational Medicine at Debiopharm.
AACR 2022 Poster Sessions
Compound Title Date and Time N°
Debio 0123 The WEE1 inhibitor Debio 0123 Tue, April 12th, #4894
enhances the efficacy of standard 9:00am-12:30pm
of care DNA Damaging agents in Section 5
lung cancer models
Multilink™ A novel antibody drug conjugate Mon, April 11th, #4882
technology linker enabling production of ADCs 1:30-5:00pm
with high drug to antibody ratios and Section 21
fast payload release for improved
Multilink™ The antibody-drug conjugate GENA-111 Mon, April 11th, #1716
technology conjugated to auristatin F shows 1:30-5:00pm
(combined with therapeutic potency in BCAM Section 21
Genome & Co’s positive epithelial cancer
xevinapant The IAP antagonist xevinapant in Tue, April 12th, #603
(rights under Merck combination with high-dose cisplatin 1:30-5:00pm
KGaA, Darmstadt, chemoradiotherapy induces NF-kB and Section 33
Germany) apoptotic pathway biomarkers
in patients with high-risk, locally
advanced squamous cell carcinoma of
advanced the head and neck
About Debio 0123
Debio 0123[https://www.debiopharm.com/pipeline/debio-0123/] is an inhibitor of WEE1 kinase, a key regulator of the G2/M and S phase checkpoints, activated in response to DNA damage, allowing cells to repair their DNA before resuming their cell cycle. WEE1 inhibition, particularly in combination with DNA damaging agents, induces DNA breaks leading to the accumulation of DNA damage. In conjunction with abrogation of other checkpoints such as those of the G1 phase of the cell cycle, the compound pushes the cells through cycle without DNA repair, promoting mitotic catastrophe and inducing apoptosis of cancer cells.
Multilink[TM][https://www.debiopharm.com/manufacturing-science/technology-pipeline/multilink/] is a new cleavable linker platform suited for multidrug attachment and compatible with any conjugation technology to produce ADCs with high DAR (drug-to-antibody ratio), allowing the loading of multiple payloads on an antibody for an enhanced therapeutic effect. This highly effective and well-tolerated linker platform is available for use of other specialty biotech or pharmaceutical companies to generate a proprietary, clinical-stage ADCs.
Xevinapant[https://www.debiopharm.com/pipeline/xevinapant/#head-and-neck-cancer], now exclusively licensed to Merck for product development and commercialization, is a potential first-in-class potent, oral, small-molecule inhibitor of IAPs (Inhibitor of Apoptosis Proteins). In preclinical studies, xevinapant restored sensitivity to apoptosis in cancer cells, thereby depriving them of one of their major resistance mechanisms to anticancer therapy. Currently in phase III clinical research, in a randomized, placebo-controlled phase II study, xevinapant has demonstrated preliminary evidence of efficacy in combination with chemoradiotherapy (CRT) in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), with a clinically significant and sustained clinical activity and an acceptable safety profile compared with CRT alone.
About Genome & Co.
Since its establishment in 2015, Genome and Company develops next waves of innovative drugs including anti-cancer microbiome therapeutics and novel target immune checkpoint inhibitors. Through continuing open innovations with global external collaborations and strategic investments, the company has expanded its microbiome pipeline into brain diseases and continues to pioneer the market in becoming a fully integrated global healthcare group capable of research, development and manufacturing of first-in-class pharmaceutical modalities including microbiome. For more information, please refer to http://genomecom.co.kr/.
Debiopharm’s commitment to patients
Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and international patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.
Visit us www.debiopharm.com/
Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
– Picture is available at AP Images (http://www.apimages.com) –
Dawn Bonine – Head of Communications
Tel: +41 (0)21 321 01 11
Source: Debiopharm International SA